BridgeBio Pharma Future Growth
Future criteria checks 2/6
BridgeBio Pharma is forecast to grow earnings and revenue by 43.6% and 40.9% per annum respectively while EPS is expected to grow by 42.8% per annum.
Key information
43.6%
Earnings growth rate
42.8%
EPS growth rate
| Biotechs earnings growth | 30.1% |
| Revenue growth rate | 40.9% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 30 Aug 2024 |
Recent future growth updates
Recent updates
BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
Aug 31BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon
Aug 17BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jun 10
BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)
Jun 03BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
Jan 11Estimating The Intrinsic Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Nov 06BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jul 02New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)
May 09Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook
Feb 28Analysts Just Made A Major Revision To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts
Jan 09BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status
Oct 11BridgeBio, Sentynl's Nulibry for rare disorder in children gets approval in EU
Sep 20BridgeBio Pharma: Down But Not Out
Aug 31BridgeBio starts dosing in phase 1 trial of BBP-671 for metabolic disorders
Aug 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 552 | -385 | -435 | N/A | 10 |
| 12/31/2025 | 237 | -582 | -572 | -461 | 14 |
| 12/31/2024 | 385 | -404 | -282 | -290 | 13 |
| 6/30/2024 | 219 | -454 | -420 | -415 | N/A |
| 3/31/2024 | 219 | -538 | -606 | -603 | N/A |
| 12/31/2023 | 9 | -643 | -529 | -528 | N/A |
| 9/30/2023 | 9 | -613 | -498 | -496 | N/A |
| 6/30/2023 | 6 | -573 | -488 | -486 | N/A |
| 3/31/2023 | 78 | -425 | -409 | -403 | N/A |
| 12/31/2022 | 78 | -481 | -426 | -419 | N/A |
| 9/30/2022 | 89 | -491 | -468 | -460 | N/A |
| 6/30/2022 | 91 | -509 | -495 | -447 | N/A |
| 3/31/2022 | 71 | -596 | -555 | -508 | N/A |
| 12/31/2021 | 70 | -563 | -546 | -498 | N/A |
| 9/30/2021 | 57 | -535 | -508 | -460 | N/A |
| 6/30/2021 | 63 | -495 | -477 | -470 | N/A |
| 3/31/2021 | 9 | -520 | -472 | -467 | N/A |
| 12/31/2020 | 8 | -449 | -407 | -400 | N/A |
| 9/30/2020 | 22 | -402 | -387 | -380 | N/A |
| 6/30/2020 | 41 | -346 | -305 | -298 | N/A |
| 3/31/2020 | 41 | -291 | -286 | -278 | N/A |
| 12/31/2019 | 41 | -261 | -256 | -254 | N/A |
| 9/30/2019 | 27 | -226 | -228 | -224 | N/A |
| 6/30/2019 | N/A | -197 | -216 | -212 | N/A |
| 3/31/2019 | N/A | -155 | -183 | -178 | N/A |
| 12/31/2018 | N/A | -131 | -155 | -137 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BBIO's revenue (40.9% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: BBIO's revenue (40.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BBIO's Return on Equity is forecast to be high in 3 years time